Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trebananib plus Bevacizumab in Recurrent Glioblastoma
NCT01609790Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2012
- Primary completion
- Oct 2015
- Modality
- Peptides, Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of trebananib in glioblastoma (GBM), Gliosarcoma (GS), sponsored by National Cancer Institute. Started Jun 2012; status: completed.
02
Drugs
trebananib
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT01609790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01609790.